COVID-19 to hurt 2020 revenues, says Merck & Co

Merck & Co has lowered its full-year revenue and earnings estimates because of the impact of COVID-19 on its business, which is focused on products administered in hospitals. <

Sanofi and Regeneron eye challenge to Merck & Co in first li...

Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results. 

Merck builds case for six-week Keytruda dosing as FDA starts...

Immuno-oncology latecomer GSK shows off PD-1 drug data

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new a...

FDA hastens development of Novartis' Kymriah in follicular l...

Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah for follicular lymphoma, after the regulator deemed it to be an advanced regene